Bio-Rad Laboratories and Perrigo Compared in Head-to-Head Review

Got story updates? Submit your updates here. ›

A head-to-head comparison of Bio-Rad Laboratories (NYSE:BIO) and Perrigo (NYSE:PRGO) examines the strengths of each company across factors like dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability, and risk. The analysis finds that Bio-Rad Laboratories has higher earnings and more volatile stock, while Perrigo has lower revenue but trades at a lower price-to-earnings ratio.

Why it matters

This analysis provides investors with a detailed look at the relative positioning of these two medical companies, helping them make more informed decisions about where to allocate their capital. Understanding the key differences between Bio-Rad and Perrigo is important for investors seeking exposure to the healthcare sector.

The details

The analysis finds that 95.9% of Perrigo shares are held by institutional investors, compared to 65.2% for Bio-Rad Laboratories. Perrigo also has a lower percentage of insider ownership at 0.7%, versus 17.1% for Bio-Rad. In terms of valuation, Perrigo trades at a lower price-to-earnings ratio than Bio-Rad, indicating it is currently the more affordable of the two stocks. However, Bio-Rad has higher earnings per share. The analysis also looks at factors like revenue, net margins, return on equity, and return on assets, finding that Bio-Rad outperforms Perrigo on 9 of the 14 metrics compared.

• The analysis was published on March 27, 2026.